Clinical Trials Logo

Clinical Trial Summary

This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive one dose of recombinant COVID-19 vaccine sequentially at different shedules of 1-3 months, 3-6 months and ≥ 6 months after two doses of vaccination, and the subjects vaccinated at different schedules will be randomly assigned to different sequential immunization groups. At the same time, each sequential immunization group will be matched with a control group with the inactivated COVID-19 vaccine (vero cells) as the booster dose.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05033847
Study type Interventional
Source National Vaccine and Serum Institute, China
Status Not yet recruiting
Phase Phase 3
Start date September 2021
Completion date January 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04901676 - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Not yet recruiting NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. Phase 2
Active, not recruiting NCT05002517 - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Phase 3
Recruiting NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Not yet recruiting NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Not yet recruiting NCT05045937 - Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
Not yet recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Active, not recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Recruiting NCT05047653 - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting NCT05035524 - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 N/A
Not yet recruiting NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1
Completed NCT04845971 - Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia Phase 2
Recruiting NCT04909476 - Tracheal Intubation in COVID-19 Patients
Active, not recruiting NCT04346147 - Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19 Phase 2
Completed NCT04381858 - Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia Phase 3
Completed NCT04363736 - A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia Phase 2
Recruiting NCT04894682 - Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
Recruiting NCT04625036 - NO-mediated Vascular Function in Covid-19 Patient